scholarly journals Repeated Doses of UVR Cause Minor Alteration in Cytokine Serum Levels in Humans

2005 ◽  
Vol 2005 (5) ◽  
pp. 298-303 ◽  
Author(s):  
Joanna Narbutt ◽  
Aleksandra Lesiak ◽  
Malgorzata Skibinska ◽  
Anna Wozniacka ◽  
Anna Sysa-Jedrzejowska ◽  
...  
Keyword(s):  
Serum Concentration ◽  
Serum Levels ◽  
Cytokine Level ◽  
High Dose ◽  
Serum Cytokine Level ◽  
Serum Cytokine ◽  
Blood Samples ◽  
Before And After ◽  
Immune Impairment ◽  
Repeated Doses

The aim of our study was to compare serum concentration of IL-1β, IL-6, IL-8, IL-10, and TNF-αin 105 healthy volunteers before and after exposure to UVR: 25 subjects (10 days of UVB), 55 (10 days of UVB or solar-simulated radiation, followed by acute UVB dose), and 25 (local high dose of UVB). In all the individuals blood samples were analyzed before and after final irradiation by chemiluminescence assay. After 10 days of UVB irradiation a statistically significant increase in serum concentration only in IL-8(P<.05)and strong tendency in TNF-α(P=.05)were observed. The applied schedules of irradiation have minor impact on serum cytokine level and still a threshold dose of UVR causing systemic immune impairment is unknown.

scholarly journals Pirfenidone inhibits cryoablation induced local macrophage infiltration along with its associated TGFb1 expression and serum cytokine level in a mouse model

Cryobiology ◽  
2018 ◽  
Vol 82 ◽  
pp. 106-111 ◽  
Author(s):  
Yangkui Gu ◽  
Govindarajan Srimathveeravalli ◽  
Liqun Cai ◽  
Eisuke Ueshima ◽  
Majid Maybody ◽  
...  
Keyword(s):  
Mouse Model ◽  
Cytokine Level ◽  
Macrophage Infiltration ◽  
Serum Cytokine Level ◽  
Serum Cytokine

scholarly journals Anti-IL-6 cytokine treatment has no impact on elevated hematocrit and splenomegaly in a polycythemia vera mouse model

2021 ◽  
Author(s):  
Conny Katrin Baldauf ◽  
Peter Müller ◽  
Tobias Ronny Haage ◽  
Stephanie Adam-Frey ◽  
Juliane Lokau ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Somatic Mutations ◽  
Jak2 V617f ◽  
Serum Levels ◽  
High Dose ◽  
Serum Cytokine ◽  
Hematological Disease ◽  
Cytokine Treatment ◽  
Leukocyte Counts ◽  
Disease Parameters

Somatic mutations in JAK2, MPL and Calreticulin and inflammation play a key role in pathophysiology of chronic myeloproliferative neoplasia (CMN). One of the most prominent cytokines elevated in serum of Polycythemia vera patients is interleukin-6 (IL-6). Currently, it is being discussed whether suppression of inflammation by anti-cytokine approaches as anti-IL-6 treatment may be therapeutically useful in CMN. We here sought to investigate the efficacy of anti-IL-6 treatment on inflammatory cytokines, hematocrit and splenomegaly in CMN like disease. JAK2-V617F knock-in mice (JAK2+/V617F) were treated for three weeks with anti-IL-6 antibody (Ab) or IgG-control. Upon anti-IL-6 Ab treatment, serum levels of CXCL2 and CXCL10 were significantly reduced. In addition, CXCL1, CCL11, M-CSF, G-CSF, IL-17, IL-12p40 and CCL2 were reduced by a factor of 0.3 - 0.8. Partly, this was also achieved by applying high-dose IgG. Hematocrit, erythrocyte and leukocyte counts were elevated in JAK2+/V617F mice but were not reduced by anti-IL6 Ab treatment. In addition, there was no apparent amelioration of splenomegaly and spleen histopathology. In conclusion, anti-IL-6 Ab treatment did not result in improvement of hematological disease parameters but was shown to modulate the serum cytokine signature.

Serum cytokine level in atopic dermatitis patients

1991 ◽  
Vol 2 (3) ◽  
pp. 232
Author(s):  
Shinichiro Yasumoto ◽  
Juichiro Nakayama ◽  
Atsumichi Urabe ◽  
Yoshiaki Hori
Keyword(s):  
Atopic Dermatitis ◽  
Cytokine Level ◽  
Serum Cytokine Level ◽  
Serum Cytokine

Angiogenic biomaker study in osteosarcoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e21507-e21507
Author(s):  
P. C. Pavoni-Ferreira ◽  
A. S. Petrilli ◽  
M. T. Alves ◽  
R. Jesus-Garcia Filho ◽  
S. R. Toledo
Keyword(s):  
Metronomic Chemotherapy ◽  
High Dose Chemotherapy ◽  
Marker Genes ◽  
High Dose ◽  
Lower Grade ◽  
Vegf Receptor ◽  
Blood Samples ◽  
Genes Expression ◽  
Before And After ◽  
Prospective Assessment

e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients. Methods: Tumor samples from 27 patients were analyzed before and after chemotherapy to determine VEGFA, VEGFR1, VEGFR2, PDGFC, SDF1 and TSP1 genes expression profile by Quantitative Real Time PCR. Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity. Results: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed. SDF1 gene has the lowest expression at all. In tumor samples, TSP1 and VEGFA expression was higher than SDF1, VEGFR2 and PDGFC expression in biopsies and surgeries (P=0.001). VEGFR1 expression was higher than VEGFR2 expression (P=0.001). PDGFC and VEGFR1 overexpression were associated with necrosis grade I and II (Huvos score) (P=0.005). VEGFA and TSP1 were overexpressed in 96% and 92% of surgery samples, respectively. In blood samples from biopsy, surgery and end of treatment there were no statistically significant changes in the marker genes expression. Conclusions: The study suggests an association between PDGFC and VEGFR1 overexpression and lower grade necrosis. TSP1 and VEGFA were the most expressed genes in all tumor samples but TSP1 was lower than VEGFA in biopsies and VEGFA was lower than TSP1 in surgery (P=0.001). Although VEGFR2 is the primary receptor of VEGF, VEGFR1 was the most expressed VEGF receptor. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document